Journal
PHARMACOGENOMICS
Volume 18, Issue 7, Pages 701-743Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2017-0194
Keywords
CYP2C19; CYP2C9; CYP2D6; drug-drug-gene interaction (DDGI); drug-drug interaction (DDI); drug-metabolizing enzyme
Categories
Funding
- Ministry of Research, Technology and Higher Education of Indonesia
Ask authors/readers for more resources
Currently, most guidelines on drug-drug interaction (DDI) neither consider the potential effect of genetic polymorphism in the strength of the interaction nor do they account for the complex interaction caused by the combination of DDI and drug-gene interaction (DGI) where there are multiple biotransformation pathways, which is referred to as drug-drug-gene interaction (DDGI). In this systematic review, we report the impact of pharmacogenetics on DDI and DDGI in which three major drug-metabolizing enzymes - CYP2C9, CYP2C19 and CYP2D6 - are central. We observed that several DDI and DDGI are highly gene-dependent, leading to a different magnitude of interaction. Precision drug therapy should take pharmacogenetics into account when drug interactions in clinical practice are expected.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available